Copyright
©The Author(s) 2021.
World J Clin Cases. Jul 26, 2021; 9(21): 5782-5793
Published online Jul 26, 2021. doi: 10.12998/wjcc.v9.i21.5782
Published online Jul 26, 2021. doi: 10.12998/wjcc.v9.i21.5782
Ref. | Trial phase | Cancer type | n | Drug(s) tested | Key outcome | Trial name (NCT) |
Kawazoe et al[15], 2020 | 2 | GC | 29 | Pembrolizumab + lenvatinib | ORR 69% (95%CI: 49-85) mPFS 7.1 mo (95%CI: 5.4-13.7) | EPOC1706 (NCT03609359) |
Kawazoe et al[16], 2020 | 2b | GC/GEJC | 54 | Pembrolizumab + SOX | ORR 72.2% (95%CI: 58.4-83.5) mPFS 6.9 mo (95%CI: 5.6-8.3) | KEYNOTE-659 (NCT03382600) |
Catenacci et al[17], 2020 | 1b-2 | GEJC | 92 | Margetuximab + pembrolizumab | ORR 18% (95%CI: 11-28) mPFS 2.73 mo | CP-MGAH22-05 (NCT02689284) |
Bang et al[9], 2019 | 2 | GC/GEJC | 25 | Pembrolizumab + SOC | ORR 60.0% (95%CI: 38.7-78.9) mPFS 6.6 mo (95%CI: 5.9-10.6) | KEYNOTE-059 (NCT02335411) |
31 | Pembrolizumab | ORR 25.8% (95%CI: 11.9–44.6) mPFS 3.3 mo (95%CI: 2.0-6.0) | ||||
Tabernero et al[10], 2019 | 3 | GC/GEJC | 256 | Pembrolizumab | ORR 14.5% (95%CI: 10.4-19.4) mPFS 2.0 mo (95%CI: 1.5-2.8) | KEYNOTE-062 (NCT02494583) |
257 | Pembrolizumab + SOC | ORR 48.6% (95%CI: 42.4-54.9) mPFS 6.9 mo (95%CI: 5.7-7.3) | ||||
250 | Placebo + SOC | ORR 36.8% (95%CI: 30.8-43.1) mPFS 6.4 mo (95%CI: 5.7-7.0) | ||||
Boku et al[18], 2019 | 2 | G/GEJ | 21 | Nivolumab + SOX | ORR 57.1% (95%CI: 34.0-78.2) mPFS 9.7 mo (95%CI: 5.8-NR) | ATTRACTION-4 (NCT02746796) |
18 | Nivolumab + CapeOX | ORR 76.5% (95%CI: 50.1-93.2) mPFS 10.6 m0 (95%CI: 5.6-12.5) |
- Citation: Liang C, Wu HM, Yu WM, Chen W. Research status on immunotherapy trials of gastric cancer. World J Clin Cases 2021; 9(21): 5782-5793
- URL: https://www.wjgnet.com/2307-8960/full/v9/i21/5782.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i21.5782